Curetis to Assist BioVersys' Antibacterial Drug Trial With Unyvero Platform
BioVersys will use the Unyvero HPN in its drug trial to test hospitalized trial candidates for antibiotic-resistant Acinetobacter infections.
The company expects the trial results to bolster sales by increasing physician confidence in the panel.
OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval
The company's cartridge for pneumonia for the Unyvero system is under review and pending approval by Chinese regulators.
BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases
A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.
Curetis, Karolinska Institute Collaborate to Identify Bacterial Co-Infections in COVID-19 Patients
The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.
Nov 1, 2019
Apr 11, 2019
Curetis 2018 Revenues Grow 17 Percent
Nov 7, 2018
Apr 19, 2018